RESUMEN
OBJECTIVE: To investigate the pharmacokinetics of pegylated liposomal doxorubicin (PLD) in Chinese tumor patients. METHODS: Ten patients with malignant tumors were given PLD (20-35 mg · m-2) combined chemotherapy. Serial plasma samples were obtained after completion of the infusion. The doxorubicin concentrations in plasma were measured using high-performance liquid chromatography (HPLC). The pharmacokinetic parameters were estimated by DAS software. The correlations between those parameters and gender were analyzed. RESULTS: The doxorubicin plasma concentration in the 10 patients ranged from 1.68 to 10.10 mg · L-1 during 0 - 168 h after administration. The AUC0-∞, CL, t1/2 and Vd were (918.6 ± 447.4) mg · L · h-1, (0.037 ± 0.02) L · h · m-2, (64.9 ± 28.4) h and (2.95 ± 0.88) L · m-2, respectively. The differences of the pharmacokinetic parameters, ie AUC0-∞, CL, t1/2 and Vd, between genders were not statistically significant. CONCLUSION: The pharmacokinetics of PLD fits one-compartment model, with long retention time, low clearance and small volume of distribution. Copyright 2012 by the Chinese Pharmaceutical Association.